Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)

Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials

(2016) Jennifer S Temel et al.   LANCET ONCOLOGY

Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials

(2015) José M Garcia et al.   LANCET ONCOLOGY

Effects of Melatonin on Appetite and Other Symptoms in Patients With Advanced Cancer and Cachexia: A Double-Blind Placebo-Controlled Trial

(2013) Egidio Del Fabbro et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

(2013) Adrian S Dobs et al.   LANCET ONCOLOGY

Disrupting Cytokine Signaling in Pancreatic Cancer

(2013) Christina Wu et al.   PANCREAS

Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia

(2013) Kun-Yun Yeh et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats

(2013) Mareike S. Pötsch et al.   Journal of Cachexia Sarcopenia and Muscle

The Role of Thalidomide and Placebo for the Treatment of Cancer-Related Anorexia-Cachexia Symptoms: Results of a Double-Blind Placebo-Controlled Randomized Study

(2012) Sriram Yennurajalingam et al.   JOURNAL OF PALLIATIVE MEDICINE

L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial

(2012) Matthias Kraft et al.   Nutrition Journal

Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

(2012) José M. Garcia et al.   SUPPORTIVE CARE IN CANCER

The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer:

(2011) Andrew J. Stewart Coats et al.   Journal of Cachexia Sarcopenia and Muscle

Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference

(2010) Thomas Kung et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cachexia: A new definition

(2008) William J. Evans et al.   CLINICAL NUTRITION